ALK-Abelló A/S (AKBLF) Q2 2026 Earnings Call August 20, 2026 7:30 AM EDT
Company Participants
Per Plotnikof – VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
Peter Halling – President, CEO & Member of Management Board
Claus Solje – Executive VP, CFO & Member of Management Board
Conference Call Participants
Benjamin Jackson – Jefferies LLC, Research Division
Thomas Bowers – SEB, Research Division
Jesper Ingildsen – DNB Carnegie, Research Division
Peter Ankersen – Nordea Markets, Research Division
Sushila Hernandez – Kempen & Co. N.V., Research Division
Presentation
Per Plotnikof
VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
Hello, everyone, and welcome to this presentation of ALK’s Q2 and first half year results. Thank you all for joining us. Let’s turn to Slide #2 with an introduction to the speakers and the agenda. My name is Per Plotnikof, I’m Head of Investor Relations. With me today are CEO, Peter Halling; and CFO, Claus Steensen Solje. Peter and Claus will walk you through the quarterly highlights, markets, product trends and financials. After a brief strategy update, we will turn to the full year outlook. And as usual, we will end the call with a Q&A session.
First, I’ll hand you over to Peter to the highlights on Slide 3. Please go ahead, Peter.
Peter Halling
President, CEO & Member of Management Board
Thank you, Per, and thank you all for taking the time to listen to this call. ALK sustained strong sales momentum in Q2 with double-digit sales growth across all regions, driven mainly by tablets and anaphylaxis products. Revenue grew by 18% in local currencies to close to DKK 1.8 billion and EBIT increased by 19%. The EBIT margin was unchanged at 25% as gross margin improvements were offset by continued investments in product launches, commercial infrastructure, R&D, AI, and other areas.